A DL-4- and TNFα-based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors.

Cellular & Molecular Immunology
Ranjita Devi MoirangthemIsabelle André

Abstract

Several obstacles to the production, expansion and genetic modification of immunotherapeutic T cells in vitro have restricted the widespread use of T-cell immunotherapy. In the context of HSCT, delayed naïve T-cell recovery contributes to poor outcomes. A novel approach to overcome the major limitations of both T-cell immunotherapy and HSCT would be to transplant human T-lymphoid progenitors (HTLPs), allowing reconstitution of a fully functional naïve T-cell pool in the patient thymus. However, it is challenging to produce HTLPs in the high numbers required to meet clinical needs. Here, we found that adding tumor necrosis factor alpha (TNFα) to a DL-4-based culture system led to the generation of a large number of nonmodified or genetically modified HTLPs possessing highly efficient in vitro and in vivo T-cell potential from either CB HSPCs or mPB HSPCs through accelerated T-cell differentiation and enhanced HTLP cell cycling and survival. This study provides a clinically suitable cell culture platform to generate high numbers of clinically potent nonmodified or genetically modified HTLPs for accelerating immune recovery after HSCT and for T-cell-based immunotherapy (including CAR T-cell therapy).

References

Jun 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·B P GiroirB Beutler
Nov 27, 1991·Biochemical and Biophysical Research Communications·M KörnerP Debré
Dec 1, 1996·Leukemia & Lymphoma·K NagafujiY Niho
Oct 14, 2003·Biochemical Pharmacology·Upasna Gaur, Bharat B Aggarwal
Jun 15, 2005·Critical Reviews in Immunology·Thomas M Schmitt, Juan Carlos Zúñiga-Pflücker
Mar 7, 2006·PLoS Pathogens·Masmudur M Rahman, Grant McFadden
Dec 7, 2007·Laboratory Investigation; a Journal of Technical Methods and Pathology·Clodia OsipoLucio A Miele
Dec 12, 2007·The Journal of Experimental Medicine·Emmanuelle M SixIsabelle André-Schmutz
Oct 1, 2008·The Journal of Experimental Medicine·Katsuto HozumiSonoko Habu
Oct 1, 2008·The Journal of Experimental Medicine·Ute KochFreddy Radtke
Feb 10, 2010·Nature Reviews. Rheumatology·Seo Young Kim, Daniel H Solomon
Jun 15, 2010·FEBS Letters·Luke W ThomasSteven W Edwards
Oct 26, 2010·Biochimica Et Biophysica Acta·Liam PorttMichael T Greenwood
May 3, 2011·Blood Cells, Molecules & Diseases·Emmanuelle M SixIsabelle André-Schmutz
Jan 24, 2012·Current Opinion in Immunology·Ellen V Rothenberg
Oct 25, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Imke Heleen BartelinkJaap Jan Boelens
Apr 10, 2013·Drug, Healthcare and Patient Safety·Tauseef AliMichael S Bronze
Mar 25, 2016·Molecular Immunology·Rudolf BicheleMartti Laan
Dec 21, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Mohammed S ChaudhryMarcel R M van den Brink
Jul 19, 2017·Cold Spring Harbor Perspectives in Biology·Hiroyuki Hosokawa, Ellen V Rothenberg
Dec 7, 2017·The Journal of Allergy and Clinical Immunology·Laura SimonsIsabelle André-Schmutz
Dec 12, 2017·The New England Journal of Medicine·Stephen J SchusterCarl H June
Apr 19, 2018·Current Pharmaceutical Biotechnology·Androulla N Miliotou, Lefkothea C Papadopoulou
Oct 30, 2018·Frontiers in Immunology·Qunfang ZhangZhenhua Dai
Jan 12, 2019·American Journal of Hematology·Waseem Qasim
Oct 2, 2019·Frontiers of Medicine·Hongli ChenAili He
Oct 28, 2019·Blood Advances·Jastaranpreet SinghJuan Carlos Zúñiga-Pflücker

❮ Previous
Next ❯

Citations

Oct 14, 2021·Biochemical Society Transactions·Steven Strubbe, Tom Taghon

❮ Previous
Next ❯

Software Mentioned

FlowJo
LimmaVoom
GeneScan
EdgeR
IPA
Cluster and Tree Conversion ( ctc ) R package
GraphPad Prism
Java TreeView
rgl R package
SigmaStat

Related Concepts

Related Feeds

CAR-T cells

Chimeric antigen receptor (CAR) T cells are cells that are genetically engineered to recognize and target specific proteins. The ability of these cells to recognize cancer antigens and eliminate tumor cells have transformed cancer immunotherapy approaches. Here is the latest research on CAR-T cells.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.